As former Chair of the Department of Pediatrics, I oversaw all aspects of the clinical, medical education, and research endeavors the department is privileged to provide. My clinical expertise is in bone marrow transplantation and the treatment of children with congenital and acquired immunological deficiencies. I have particular expertise in treating genetic diseases that impair hematopoiesis — the formation of blood cells — as well as pediatric leukemias. I am also an authority on transplantation immunology and cellular therapies.
I’ve always been fascinated by the immunology of transplantation and our ability to use this approach to cure diseases. I was involved in the first transplant of bone marrow from an unrelated donor to a patient in 1973. This opened the possibility of a transplant to the majority of patients who lack a matched brother or sister. Since then, we have greatly refined this approach. In fact most of the transplants we perform are now from unrelated donors.
I also conduct laboratory and clinical research, and have led national studies of new therapies for children with genetic immunodeficiencies and both adults and children with leukemia and other life-threatening blood diseases. I and my colleagues developed and introduced methods for removing T cells from the donor’s transplant. (T cells are the white blood cells that can attack the tissues of the patient and cause a complication called graft-versus-host disease [GvHD]). This approach has proven to be an effective way to prevent GvHD, and has allowed us to transplant marrow from genetically half-matched donors, such as a mother or father, without causing severe or fatal GvHD. We’ve also developed and introduced in clinical trial, new immune cell therapies to manage other potential complications of transplantation, such as Epstein-Barr-virus lymphomas and cytomegalovirus infections. Today there is no more “boy in the bubble,” thanks to the advances we’ve made in bone marrow transplantation.
My fellow scientists and I are now developing cellular therapies that could be used to enhance the resistance of bone marrow transplant recipients to not only serious infections but also their underlying cancers. We’re aiming to create novel systems to elicit an immune response in the patient against infectious organisms or residual cancer cells.
I am privileged to work with a dedicated and experienced team of professionals who have the capacity to assess clinical challenges and develop innovative solutions. We share a passion for delivering good medicine. We’ve also developed support systems for patients and their families that are second to none.
I have shared my experience and knowledge with fellows and residents, many of whom have gone on to establish bone marrow transplant programs at institutions around the world. I am past-President and currently a member of the Board of the Damon Runyon-Walter Winchell Cancer Fund, and on the Board of the Children’s Oncology Society of New York, which runs the local Ronald McDonald House. I have won several awards for my work, including honors from the American Society of Clinical Oncology, the Society of Translational Oncology, the American Society for Blood and Marrow Transplantation, and Leiden University in The Netherlands.
- Clinical Expertise: Pediatric Oncology; Allogeneic and Autologous Bone Marrow and Peripheral Blood Stem Cell Transplantation; Congenital and Acquired Diseases of Hematopoiesis and Immunity
- Awards and Honors: New York Magazine Top Doctors (2002-2016)
- Languages Spoken: English
- Education: MD, University of Rochester School of Medicine
- Residencies: University of Minnesota Hospitals; Children's Hospital Medical Center (Boston)
- Fellowships: Children's Hospital Medical Center (Boston); Beth Israel Hospital (Boston)
- Board Certifications: Pediatrics
Shank B, Chu FC, Dinsmore R, et al. Hyperfractionated total body irradiation for bone marrow transplantation. Results in seventy leukemia patients with allogeneic transplants. Int J Radiat Oncol Biol Phys 1983; 9 :1607
Brochstein JA, Kernan NA, Groshen S, et al. Allogeneic bone marrow transplantation after hyperfractionated total-body irradiation and cyclophosphamide in children with acute leukemia. N Engl J Med 1987; 317 :1618
Papadopoulos EB, Carabasi MH, Castro-Malaspina H, et al. T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease. Blood 1998 Feb 1;91(3):1083-90 1998; 91 :1083
Boulad F, Steinherz P, Reyes B, et al. Allogeneic bone marrow transplantation versus chemotherapy for the treatment of childhood acute lymphoblastic leukemia in second remission: a single-institution study. J Clin Oncol 1999; 17 :197
Gillio AP, Boulad F, Small TN, et al. Comparison of long-term outcome of children with severe aplastic anemia treated with immunosuppression versus bone marrow transplantation. Biol Blood Marrow Transplant 1997; 3 :18
O’Reilly RJ, Kapoor N, Pollack M, et al. Reconstitution of immunologic function in a patient with severe combined immunodeficiency following transplantation of marrow from an HLA-A,B,C nonidentical but MLC-compatible paternal donor. Transplant Proc 1979; 11 :1934
Reisner Y, Kapoor N, Kirkpatrick D, et al. Transplantation for severe combined immunodeficiency with HLA-A,B,D,DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. Blood 1983; 61 :341
Brochstein JA, Gillio AP, Ruggiero M, et al. Marrow transplantation from human leukocyte antigen-identical or haploidentical donors for correction of Wiskott-Aldrich syndrome. J Pediatr 1991; 119 :907
Castro-Malaspina H, Childs B, Laver J, et al. Hyperfractionated total lymphoid irradiation and cyclophosphamide for preparation of previously transfused patients undergoing HLA-identical marrow transplantation for severe aplastic anemia. Int J Radiat Oncol Biol Phys 1994; 29 :847
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Led by Richard J. O'Reilly
- A Phase II Trial of Transplants from HLA-Compatible Donors with T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System for the Treatment of Patients with Hematologic Malignancies and Disorders
- A Prospective Natural History Study of the Diagnosis, Treatment, and Outcomes of Children with SCID Disorders
- A Retrospective and Cross-Sectional Analysis of Patients Treated for Severe Combined Immunodeficiency (SCID)
Clinical Trials Co-Investigated by Richard J. O'Reilly
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more